Some pharma companies search for new biological targets and then develop drugs based on those findings. He was also a cofounder of Tango Therapeutics and Relay Therapeutics, which have raised $55 million and $520 million respectively. “We want competition in the biopharmaceutical space for the advantage of patients.”Just because the drugs are cheaper, however, doesn’t mean they will be preferred. On the other hand, most of these drugs match the price of their competitors and don’t undercut them, as Borisy is proposing. Pharmaceutical companies are notoriously litigious, but Borisy believes his company will be safe from patent infringement lawsuits.

Source: Forbes January 12, 2020 15:28 UTC